28 January 2018 - Medicines Australia welcomes the Government’s announcement of an outcome from the post-market review of the Life Saving Drugs Programme.

We particularly welcome the recognition that medicines that reduce the level and duration of disability and improve quality of life have a significant impact.

Milton Catelin, Chief Executive of Medicines Australia says the sector is looking forward to working with the Government to develop appropriate guidance on this expanded criteria.

“It is important to bring certainty about access to life saving drugs to the patients who need them. We hope that the changes to the LSDP will provide this,” said Mr Catelin.

Read Medicines Australia press release